Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | HNF4A | P41235 | 2/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.89 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.89 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 5/20 | 0.64 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.55 |
| ▸ | GUSB | P08236 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30075246 | 1.00 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL21385358 | 1.00 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL6266629 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL1048686 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL6266631 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL29938670 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL23143202 | 0.91 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL30075263 | 0.91 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL29759537 | 0.91 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL8229587 | 0.89 | PTPN1 (0.81) | PTPN1HNF4APTPN6PTPN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007047815-A2 | DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| CN-110208540-B | Methods and compositions for the detection and treatment of preeclampsia | 耶鲁大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-113226381-B | Naphthalene derivative conjugated metal oxide nanoparticles as contrast agents for detection of beta-amyloid plaques by magnetic resonance imaging | 古巴神经科学中心 | 2023-09-19 | — | — | CN | disclosed |
| CN-110187119-B | Methods and compositions for the detection and treatment of preeclampsia | 耶鲁大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-110187121-B | Methods and compositions for the detection and treatment of preeclampsia | 耶鲁大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-110187120-B | Methods and compositions for the detection and treatment of preeclampsia | 耶鲁大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-109789129-B | Autophagy-improving material and use thereof | 延世大学校产学协力团 | 2022-04-29 | — | — | CN | disclosed |
| US-20210290782-A1 | METAL OXIDES NANOPARTICLES CONJUGATED WITH NAPHTHALENE DERIVATIVES AS CONTRAST AGENTS FOR THE DETECTION OF BETA AMYLOID PLAQUES BY MAGNETIC RESONANCE IMAGES | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2021-09-23 | — | — | US | disclosed |
| EP-3878475-A1 | METAL OXIDES NANOPARTICLES CONJUGATED WITH NAPHTHALENE DERIVATIVES AS CONTRAST AGENTS FOR THE DETECTION OF BETA AMYLOID PLAQUES BY MAGNETIC RESONANCE IMAGES | Centro De Neurociencias De Cuba (CU) | 2021-09-15 | — | — | EP | disclosed |
| CN-107412788-B | Novel compound for imaging Tau protein accumulated in brain | 国立研究开发法人量子科学技术研究开发机构 | 2021-06-18 | — | — | CN | disclosed |
| WO-2015067216-A1 | NOVEL USE OF A DIMETHYL SULPHOXIDE (DMSO) EXTRACT OR FRACTION FROM GRAPTOPETALUM SP. | HUANG CHI-YING (CN) | 2015-05-14 | — | — | WO | disclosed |
| CN-102483418-B | Methods and compositions for the detection and treatment of preeclampsia | UNIV YALE | 2015-01-07 | — | — | CN | disclosed |
| CN-102483418-A | Methods and compositions for the detection and treatment of preeclampsia | UNIV YALE | 2012-05-30 | — | — | CN | disclosed |
| WO-1999024394-A9 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIV PITTSBURGH (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6168776-B1 | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH | 2001-01-02 | — | — | US | disclosed |
| EP-1028941-A2 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2000-08-23 | — | — | EP | disclosed |
| CN-1261906-A | Alkyl, alkenyl and alkynyl chrysamine G derivatives for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition | UNIV PITTSBURGH (US) | 2000-08-02 | — | — | CN | disclosed |
| EP-0977815-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND $i(IN VIVO) IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999024394-A2 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1998047969-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290782-A1 | METAL OXIDES NANOPARTICLES CONJUGATED WITH NAPHTHALENE DERIVATIVES AS CONTRAST AGENTS FOR THE DETECTION OF BETA AMYLOID PLAQUES BY MAGNETIC RESONANCE IMAGES | L1CAM, NUCB2, TSPO | PTPN1 4235/4885HNF4A 1954/4885PTPN6 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.